Skip to main content

Advertisement

SpringerLink
Log in

Resolution of New-Onset Diabetes After Radical Pancreatic Resection Predicts Long-term Survival in Patients with Pancreatic Ductal Cell Adenocarcinoma

  • Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To demonstrate the effect of diabetes mellitus (DM) (stratified by long-term/new-onset presurgical diabetes, resolved/unresolved postsurgical diabetes) on prognosis for pancreatic ductal cell adenocarcinoma (PDAC) after radical resection.

Methods

One hundred ninety-nine patients who underwent radical resection for PDAC between 2007 and 2011 at Ruijin Hospital (Shanghai, China) were retrospectively analyzed. Clinical and pathologic characteristics, surgical and adjuvant chemotherapy related outcomes, disease-free survival (DFS), and postoperative survival were compared among patients with long-term (≥2 years)/new-onset (<2 years) presurgical diabetes and resolved/unresolved postsurgical diabetes. Univariate and multivariable analysis was performed to determine factors associated with DFS and overall survival (OS).

Results

Of 199 patients, 90 (44.7 %) had DM, 64 of which were new onset and 26 of which were long-standing. Resolution of DM after radical pancreatic resection was observed in 65 % (42 of 64) in the new-onset group, but in none of the long-standing group. Resolved new-onset DM patients had larger, well-differentiated tumors compared to patients with unresolved new-onset DM. Patients with long-standing DM had shorter postoperative DFS and OS than nondiabetic/new-onset DM, whereas postoperative resolved new-onset DM is associated with longer DFS and OS than unresolved DM. Morbidity was higher and postoperative hospital stay was longer in patients with new-onset DM compared with patients with long-standing DM and patients without DM. There was no difference in the adjuvant chemotherapy toxicity rate among patients with long-standing or new-onset DM and those without DM.

Conclusions

Different status of DM has different effects on outcome after resection for PDAC. Long-standing DM is related to progression of disease, whereas postsurgical resolved new-onset DM is a favorable prognostic factor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  2. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.

    Article  PubMed  CAS  Google Scholar 

  3. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.

    Article  PubMed  CAS  Google Scholar 

  4. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.

    Article  PubMed  CAS  Google Scholar 

  5. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88–95.

    Article  PubMed  Google Scholar 

  6. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer. 2012;19:F9–26.

    Article  PubMed  CAS  Google Scholar 

  7. Li D. Diabetes and pancreatic cancer. Mol Carcinog. 2012;51:64–74.

    Article  PubMed  CAS  Google Scholar 

  8. Wu JM, Kuo TC, Yang CY, et al. Resolution of diabetes after pancreaticoduodenectomy in patients with and without pancreatic ductal cell adenocarcinoma. Ann Surg Oncol. 2013;20:242–9.

    Google Scholar 

  9. Chu CK, Mazo AE, Goodman M, et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17:502–13.

    Article  PubMed  Google Scholar 

  10. Ganti AK, Potti A, Koch M, et al. Predictive value of clinical features at initial presentation in pancreatic adenocarcinoma: a series of 308 cases. Med Oncol. 2002;19:233–7.

    Article  PubMed  Google Scholar 

  11. Talar-Wojnarowska R, Gasiorowska A, Strzelczyk J, Janiak A, Malecka-Panas E. Prognostic factors in the operative and palliative treatment of pancreatic cancer. Neoplasma. 2003;50:383–7.

    PubMed  CAS  Google Scholar 

  12. Wakasugi H, Funakoshi A, Iguchi H. Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol. 2001;6:50–4.

    Article  PubMed  CAS  Google Scholar 

  13. Cannon RM, LeGrand R, Chagpar RB, et al. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford). 2012;14:228–35.

    Article  PubMed  Google Scholar 

  14. Kang SP, Saif MW. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the 2010 ASCO Annual Meeting. Chicago, IL. June 4–8, 2010. JOP. 2010;11:334–5.

    PubMed  Google Scholar 

  15. Ben Q, Xu M, Jiang Y, et al. Clinical profiles and long-term outcomes of patients with pancreatic ductal adenocarcinoma and diabetes mellitus. Diabetes Metab Res Rev. 2012;28:169–76.

    Google Scholar 

  16. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

    Article  PubMed  Google Scholar 

  17. Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134:981–7.

    Article  PubMed  CAS  Google Scholar 

  18. Basso D, Brigato L, Veronesi A, et al. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res. 1995;15(6B):2585–8.

    Google Scholar 

  19. Basso D, Valerio A, Brigato L, et al. An unidentified pancreatic cancer cell product alters some intracellular pathways of glucose metabolism in isolated rat hepatocytes. Pancreas. 1997;15:132–8.

    Article  PubMed  CAS  Google Scholar 

  20. Zhou L, Zhang R, Wang L, et al. Upregulation of REG Ialpha accelerates tumor progression in pancreatic cancer with diabetes. Int J Cancer. 2010;127:1795–803.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Supported in part by Youth Foundation of Shanghai Municipal Health Bureau (No. 122) and Young Teachers Program of Shanghai University.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

    Xiang Yi He MD, PhD, Wei Yan Yao MD, PhD & Yao Zong Yuan MD, PhD

  2. Key Laboratory of Shanghai Gastric Neoplasms, Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Jian Fang Li MD

Authors
  1. Xiang Yi He MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian Fang Li MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Yan Yao MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yao Zong Yuan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yao Zong Yuan MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, X.Y., Li, J.F., Yao, W.Y. et al. Resolution of New-Onset Diabetes After Radical Pancreatic Resection Predicts Long-term Survival in Patients with Pancreatic Ductal Cell Adenocarcinoma. Ann Surg Oncol 20, 3809–3816 (2013). https://doi.org/10.1245/s10434-013-3095-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3095-2

Keywords

Search

Navigation